5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Advanced Enzyme Technologies Ltd.

•
advancedenzymes.comBSE: 540025NSE: ADVENZYMES
Market Cap₹ 3,354 Cr.
Current Price
High / Low₹ 419 / 252
Stock P/E20.2
Book Value₹ 148
Price to Book1.76
Dividend Yield1.79 %
ROCE15.3 %
ROE11.4 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2024 • Human Nutrition: 67.2% • Bio-Process: 20.9% • Animal Nutrition: 10.8%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has consistently been profitable over the last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.99x)
  • Company has been maintaining a healthy dividend payout of 35.5%
  • Company comfortably covers its interest (63.3x coverage)
  • Company generates healthy free cash flow

CONS

  • Company has delivered a poor profit growth of 2.8% over past five years
  • Recurring exceptional / one-off items are inflating headline profit
  • Operating margins have contracted to 30.7% from 33.8%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.ADVENZYMES299.5020.223353.691.7938.59-4.58189.792.0915.2726.85
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
147158161158155146169167186185172203190
103107107102103104114122129124123140149
Operating Profit44515455514255465660496341
OPM %29.89%32.51%33.41%35.08%33.11%29.03%32.67%27.28%30.35%32.55%28.70%31.09%21.34%
7614-67108991020713
Interest1111111111111
Depreciation9999999101010101010
Profit before Tax41485940494253435560586054
Tax %29.05%26.56%27.82%24.59%28.15%20.90%26.69%38.50%26.34%24.87%25.92%24.33%27.91%
Net Profit0000353339274045434539
2.583.083.742.533.052.943.362.373.573.873.803.843.31

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
329391420444502529541624637746750
178227237241269327383419441516536
Operating Profit151164183203233203157205196229213
OPM %46.04%41.82%43.51%45.75%46.34%38.27%29.13%32.91%30.70%30.74%28.43%
3366962122334750
Interest49543334542
Depreciation1318212629353535374040
Profit before Tax137139162179210171140188187233231
Tax %32.18%32.68%28.44%25.74%28.00%27.63%26.02%27.08%28.50%25.34%25.70%
Net Profit9394116133151124104137134174172
EPS8.278.069.9411.5613.0410.689.4511.9211.7215.07—
Dividend Payout %4.88%6.19%6.03%5.18%6.89%9.35%10.59%42.78%44.37%35.49%—

COMPOUNDED SALES GROWTH

10 Years:
10%
5 Years:
8%
3 Years:
11%

COMPOUNDED PROFIT GROWTH

10 Years:
8%
5 Years:
3%
3 Years:
17%

STOCK PRICE CAGR

10 Years:
1%
5 Years:
-4%
3 Years:
-2%
1 Year:
-11%

RETURN ON EQUITY

10 Years:
15%
5 Years:
11%
3 Years:
11%
Last Year:
11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 13

₹ 478.50

Bord Resolution for the Buyback

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22222222222222222222
Minority Interest21232628625249474851
4415346538149461,0661,2131,2991,3941,600
46662825222928403223
Trade Payables11171010151824161940
41656673827374979697
Total Liabilities5837278059711,1491,2601,4111,5211,6111,834
421491495563604619649650679692
Capital Work in Progress135551016312251
00111124121102360403480584
6876778094121124148157177
000000099115145
Cash & Bank8612383198274123127108116
839694117127135139645068
Total Assets5837278059711,1491,2601,4111,5211,6111,834

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
160160176192220177177141142157
Cash from Investing-60-78-125-44-26-4-298-65-89-74
Cash from Financing-65-2-43-39-26-48-26-59-73-70
-1836-395811170-18417-1912

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
43.0242.9542.9343.0843.0843.0743.0443.2643.24
12.0312.6312.5811.9023.4525.4125.8525.5026.70
8.088.028.178.198.456.415.515.414.77
Government0.000.000.000.000.000.000.000.000.00
36.8836.4136.3236.8325.0225.1025.6025.8425.27

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Copy of Newspaper Publication

2026-09-10 - Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-08
Updates

2026-09-08 - Advanced Enzyme Technologies Limited has informed the Exchange regarding 'Extinguishment of Equity Shares'.

2026-09-05
General Updates

2026-09-05 - Intimation of receipt of request from a few promoter group members for reclassification from Promoter Group category to Public category shareholders under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

2026-08-18
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-18 - Advanced Enzyme Technologies Limited has informed the Exchange about Transcript

2026-08-13
General Updates

2026-08-13 - Advanced Enzyme Technologies Limited has informed the Exchange about General Updates

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Advanced Enzyme Technologies Limited has informed the Exchange about Link of Recording

2026-08-11
Buyback

2026-08-11 - Advanced Enzyme Technologies Limited has submitted the Exchange the Board Resolution of Buyback

2026-08-11
Public Announcement - Buyback of Shares

2026-08-11 - Advanced Enzyme Technologies Limited has informed the Exchange about public Announcement - Buyback of Shares

2026-08-10
Copy of Newspaper Publication

2026-08-10 - Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for ADVENZYMES

Loading news…

🤖

AI Stock Analyst

Advanced Enzyme Technologies Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login